Please login to the form below

BCMA

This page shows the latest BCMA news and features for those working in and with pharma, biotech and healthcare.

GSK’s anti-BCMA drug leads crowded CHMP recommendations

BCMA protein is expressed at varying levels in myeloma patients and BCMA membrane expression is universally detected in myeloma cell lines. ... The positive recommendation from the CHMP means that GSK’s Blenrep will be the first anti-BCMA treatment

Latest news

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Barron has said Zejula is one of three that he expects to drive the regrowth of GSK as an oncology player, along with recently-filed BCMA antibody-drug conjugate belantamab mafodotin
Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma.
FDA begins speedy review of BMS’ CAR-T liso-cel

In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for multiple myeloma. ... However, on that front there are a number of rivals already developing anti-BCMA therapeutics,
FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

If approved will become first BCMA targeting drug for myeloma. GlaxoSmithKline looks set to win the race to bring a BCMA-targeting drug to market for multiple myeloma, after gaining a ... This includes belantamab mafodotin, which is a particularly
GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus

cancers. GSK’s other big hope in oncology is its BCMA antibody drug-conjugate GSK2857916, which is being studied in multiple myeloma and could reach market as early as 2020.

More from news
Approximately 6 fully matching, plus 46 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... BCMA to which Celgene already has access.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Highlights in haematologic malignancy from ASH 2018

Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....